Abstract: There is disclosed a process for the biotechnological resolution, by enzymatic esterification of the corresponding racemic mixture of the S(+) and R(-) optical isomers of the oxazolidinonic compounds having formula (I): ##STR1## wherein R represents a, linear or branched, C.sub.1 -C.sub.8 alkyl group, which process is characterized in that, the racemic 3-alkyl-5-hydroxymethyl-oxazolidin-2-one derivative of formula (I) is reacted with an esterifying compound, selected from esters having formula (III): ##STR2## wherein R represents a, linear or branched, C.sub.1 -C.sub.10 alkyl or alkenyl group and R" represents a linear or branched, C.sub.1 -C.sub.4 alkyl, alkenyl group, a haloalkyl (chlorine, bromine) group or a diacyl glycerolic group or from acids having formula (IV):R'"--COOH (IV)wherein R'" represents a, linear or branched, C.sub.1 -C.sub.20 alkyl or alkenyl group or from anhydrides having formula (V): ##STR3## wherein R.sup.IV represents a, linear or branched, C.sub.1 -C.sub.

Abstract: As the novel antibiotic TAN-950A having the structural formula ##STR1## and salt thereof of the present invention show antimicrobial action against fungi, they can be used in the therapeutics of fungal infections, in human and other animals etc. by oral, parenteral or external administration.

Abstract: A process for producing a primary or secondary alcohol derivative of a phosopholipid which comprises reacting the phospholipid with a primary or secondary alcohol in the presence of phospholipase DM.

Abstract: A process for producing a sphingophospholipid derivative comprising reacting a sphingophospholipid with a specified compound having an alcoholic hydroxyl group selected from the group consisting of specified primary alcohol compounds, specified secondary alcohol compounds and specified saccharides or their phenol glycosides in the presence of phospholipase DM.

Abstract: Virginiamycin M.sub.1 having the Formula: ##STR1## and virginiamycin M.sub.1 analogs having the Formulae I-IV: ##STR2## Virginiamycin M.sub.1 and the analogs I-IV are antagonists of cholecystokinin (CCK) and gastrin. Cholecystokinin antagonists are useful as analgesics and in the treatment and prevention of disorders of the gastrointestinal, central nervous and appetite regulatory systems in animals, especially humans. Gastrin antagonists are useful in blocking the receptors for gastrin in humans and may function as agents for the treatment of ulcers, tumors or other gastrointestinal disorders. The compounds of Formulae I-IV are also antibiotics and are useful as antimicrobial agents in animals including man and are useful as food additives to promote feed utilization in animals. Virginiamycin M.sub.1 and the analogs of Formula I, III, and IV are produced by the controlled aerobic fermentation of a strain of Streptomyces olivaceus, ATCC No.

Abstract: The invention relates to a novel microorganism of the genus Rhodococcus, to the use thereof in a process for the microbiological degradation of amino-s-triazines and cyanuric acid in wastewaters, as well as to a process for the microbiological degradation of s-triazine derivatives to biomass or to degradation products such as NH.sup.30.sub.4 and/or chloride, which comprises the combined use of said microorganism with Pseudomonas spp.

Abstract: A compound having the formula ##STR1## can be prepared by enzymatically coupling a compound of the formula ##STR2## with a compound of the formula ##STR3## in the presence of Escherichia coli acylase at a pH of from about 4.0 to about 6.0.

Abstract: A process for the stereospecific inversion of the [S] enantiomer of an .alpha.-aryloxypropionic acid of formula I: ##STR1## wherein G is OR.sup.1 or ##STR2## R.sup.1 is hydrogen or a protecting group and R.sup.2 is hydrogen or methyl, U and V each independently represent hydrogen or halogen, and R is a carboxyl group, or an enzymic equivalent thereof, which process comprises contacting said [S] enantiomer with a microorganism having a stereospecific inverting enzyme system, or with an extract of the microorganism contacting said enzyme system, to convert the [S] enantiomer to the corresponding [R] enantiomer.

Abstract: A process for the stereospecific inversion of the [S] enantiomer of an .alpha.-aryloxypropionic acid of formula I: ##STR1## wherein E is OR.sup.1 or ##STR2## R.sup.1 is an unsubstituted or substituted aryl or heterocyclic ring system, and R.sup.2 is hydrogen or methyl, U and V each independently represent hydrogen or halogen and R is a carboxyl group, or an enzymic and herbicidal equivalent thereof, which process comprises contacting said [S] enantiomer with a microorganism having a stereospecific inverting enzyme system, or with an extract of the microorganism containing said enzyme system, to convert the [S] enantiomer to the corresponding [R] enantiomer.

Abstract: Compounds of the formula (I): ##STR1## and pharmaceutically acceptable salts thereof wherein R.sup.1 is hydrogen, alkyl of 1 to 10 carbon atoms or acyl of 1 to 6 carbon atoms; R.sup.2 is hydrogen or halo; R.sup.3 is hydrogen, alkyl of 1 to 6 carbon atoms or acyl of 1 to 6 carbon atoms; R.sup.4 is hydrogen or alkyl of 1 to 6 carbon atoms; R.sup.5 is hydrogen or acyl of 1 to 6 carbon atoms; X is CONH.sub.2, hydroxyalkyl of 1 to 4 carbon atoms or COOR.sup.6 wherein R.sup.6 is hydrogen or alkyl of 1 to 4 carbon atoms; and Y is CONH.sub.2, hydroxyalkyl of 1 to 4 carbon atoms or COOR.sup.7 wherein R.sup.7 is hydrogen, alkyl of 1 to 10 carbon atoms or benzyl are useful for inhibiting the activity of amino-peptidase B, exhibit immunomodulating action against living organisms and exhibit anti-inflammatory activity.

Abstract: The invention relates especially to 2-(3'-hydroxypyrid-2'-yl)-2-thiazoline-4-carboxylic acid derivatives of the formula (I) and salts and also certain metal complexes of these compounds, processes for their manufacture, pharmaceutical agents containing such compounds and the use of these compounds. ##STR1## In the formula, R.sup.1 represents free, etherified or esterified hydroxy, R.sup.2 represents hydrogen or an aliphatic, carbocyclic or carbocyclic-aliphatic radical having 1-12 carbon atoms, and R.sup.3 represents hydrogen or an unsubstituted aliphatic radical having 1-7 carbon atoms.The compounds of the formula (I) can be used, for example, for the abstraction of heavy metals from the organism of warm-blooded animals and/or they have an antibiotic action.

Abstract: A novel bioactive substance of the formula ##STR1## is produced in the fermentation of Streptomyces clavuligerus. Also disclosed is a fermentation method of making the substance. The substance exhibits in vitro antimicrobial activity in defined minimal medium and antifungal activity in natural medium.

Abstract: A method for preparing vitamin B.sub.1 in a fermentation process involves cultivating mutants of yeast of the genus Saccharomyces Meyen emend Reess that synthesize this vitamin from sugars and inorganic salts and excrete it from living cells into fermentation media.